Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blue Water Ventures International Inc (OP: BWVI )

0.1433 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.1433
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1433
Today's Range 0.1433 - 0.1433
52wk Range 0.0880 - 0.2900
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
EXCLUSIVE: Lessons From Psychedelics Markets Through Business, Legal And Reciprocity Lenses
This year’s edition of Benzinga’s Psychedelics Capital Conference hosted some of the most knowledgeable panelists and hot-button discussions currently in the space. 
Via Benzinga
Zappy Zapolin Talks Psychedelics And Breakthrough Delivery Methods: The Future Has Arrived And It's Awesome
Mike ‘Zappy’ Zapolin, Chief Visionary Officer of Psycheceutical Bioscience, Inc (OTCPK: BWVI), whom we'll call Zappy, shared his vision for the future of psychedelics at the... 
Via Benzinga

Performance

YTD
+3.84%
+3.84%
1 Month
-7.85%
-7.85%
3 Month
-10.72%
-10.72%
6 Month
-13.67%
-13.67%
1 Year
-28.74%
-28.74%

More News

Read More
The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.’s (OTCPK:BWVI) Novel Topical Ketamine Delivery
Via ACCESSWIRE
Psyched: MDMA Therapy Advances With FDA, Alternatives For Alcohol Addiction, Prince Harry In The Spotlight And More
Via Benzinga
This Groundbreaking Ketamine Topical Cream Is Capturing Rick Doblin's Attention
Via Benzinga
What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry
Via Benzinga
Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
What If There Was A Topical Cream That Treated PTSD Without Side Effects? — Psycheceutical Bioscience, Inc (OTCPK: BWVI) Is Pioneering A Possible Solution
Via News Direct
What If There Was A Topical Cream That Treated PTSD Without Side Effects? — Psycheceutical Bioscience, Inc (OTCPK: BWVI) Is Pioneering A Possible Solution
Via TheNewswire.com
Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
Via Benzinga
Breakthrough Treatment For PTSD? This Ketamine Cream Showing Promise In Alleviating Symptoms
Via Benzinga
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
Via Benzinga
Benzinga's Psychedelics Capital Conference: Meet An Unrivaled Group Of Advisors And Fund Partners
Via Benzinga
Psycheceutical Bioscience, Inc (OTCPK: BWVI) Could Be Revolutionizing Psychedelic Health Care By Developing The First Ever Topical Psychedelic Cream To Treat PTSD
Via TheNewswire.com
Psycheceutical Bioscience, Inc (OTCPK: BWVI) Could Be Revolutionizing Psychedelic Health Care By Developing The First Ever Topical Psychedelic Cream To Treat PTSD
Via News Direct
BioMedNewsBreaks – Psycheceutical Bioscience Inc. (BWVI) Inks Agreement for First-Ever Clinical Trials of a Proprietary Ketamine Topical Cream to Treat PTSD
Via Investor Brand Network
Exposures Product Safety
Novel Ketamine Topical Cream To Treat PTSD Gets First In-Human Trials
Via Benzinga
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
Zappy Zapolin's Psycheceutical Files Patent, Hopes Ketamine Topical Can Treat PTSD
Via Benzinga
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
Psycheceutical Bioscience, Inc. Announces Medical Advisory Board
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.